Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)

Ajay K. Nooka, Jonathan L. Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne A. Efebera, Brandi Reeves, Tanya M. Wildes, Sarah A. Holstein, Larry D. Anderson, Jr., Ashraf Z. Badros, Leyla O. Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Usmani, Peter M. Voorhees

Blood (2022) 140 (Supplement 1): 10154–10156.

https://doi.org/10.1182/blood-2022-162473

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Blood (2022) 140 (Supplement 1): 7278–7281.

https://doi.org/10.1182/blood-2022-162339

Published: 2022

Journal Articles

Ropegiterferon Alfa-2b-Njft for Treatment Myeloproliferative Neoplasms: A Single Institution Experience

Callie Berkowitz, Sheh-Li Chen, Brandi Reeves

Blood (2022) 140 (Supplement 1): 12254–12255.

https://doi.org/10.1182/blood-2022-164733

Published: 2022

Journal Articles

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Blood (2022) 140 (Supplement 1): 10144–10147.

https://doi.org/10.1182/blood-2022-160451

Published: 2022

Journal Articles

Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood (2022) 140 (Supplement 1): 4834–4838.

https://doi.org/10.1182/blood-2022-162741

Published: 2022

Journal Articles

INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study

Justin Watts, Anthony M. Hunter, Alessandra Iurlo, Blanca Xicoy, Francesca Palandri, Brandi Reeves, Alessandro M. Vannucchi, Xuejun Chen, Francis Seguy, Feng Zhou, Fred Zheng, Pankit Vachhani

Blood (2022) 140 (Supplement 1): 9696–9697.

https://doi.org/10.1182/blood-2022-169740

Published: 2022

Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Blood (2022) 140 (Supplement 1): 1146–1149.

https://doi.org/10.1182/blood-2022-162313

Published: 2022

Journal Articles

P-Selectin Deficiency Reduces Acute Vascular Complications but Not Chronic Organ Damage in Sickle Cell Mice

Erica Sparkenbaugh, Malgorzata Kasztan, Megan D Miller, Elizabeth A Binning, Christina M Abrams, Brandi Reeves, Prithu Sundd, Rafal Pawlinski

Blood (2021) 138 (Supplement 1): 187.

https://doi.org/10.1182/blood-2021-153671

Published: 2021

Journal Articles

Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies

Blood (2021) 138 (Supplement 1): 2852.

https://doi.org/10.1182/blood-2021-149028

Published: 2021

Journal Articles

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin

Blood (2021) 138 (Supplement 1): 2723.

https://doi.org/10.1182/blood-2021-148533

Published: 2021

Journal Articles

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance

Blood (2021) 138 (Supplement 1): 79.

https://doi.org/10.1182/blood-2021-149024

Published: 2021

Journal Articles

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-137109

Published: 2020

Journal Articles

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin

Peter M. Voorhees, Cesar Rodriguez, MD, Brandi Reeves, MD, Nitya Nathwani, MD, Luciano J. Costa, MD PhD, Yana Lutska, PharmD, Padma Bobba, Daniela Hoehn, Huiling Pei, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas S. Lin, MD PhD, Paul G. Richardson, MD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-137105

Published: 2020

Journal Articles

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Blood (2020) 136 (8): 936–945.

https://doi.org/10.1182/blood.2020005288

Published: 2020

Includes: Supplemental data

Journal Articles

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Blood (2019) 134 (Supplement_1): 691.

https://doi.org/10.1182/blood-2019-123465

Published: 2019

Journal Articles

Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1

Sara Bringhen, Peter M. Voorhees, MD, Torben Plesner, MD DSc, Ulf-Henrik Mellqvist, MD PhD, Brandi Reeves, MD, Pieter Sonneveld, Catriona Byrne, RN, Eva Nordström, MSc, Johan Harmenberg, MD PhD, Jakob Obermüller, MSc, Paul G. Richardson, MD

Blood (2019) 134 (Supplement_1): 1839.

https://doi.org/10.1182/blood-2019-124828

Published: 2019

Journal Articles

Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Peter M. Voorhees, MD, Cesar Rodriguez, MD, Brandi Reeves, MD, Nitya Nathwani, MD, Luciano J Costa, MD PhD, Yana Lutska, PharmD, Daniela Hoehn, MDPhD, Huiling Pei, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas Lin, MD PhD, Paul Richardson

Blood (2018) 132 (Supplement 1): 151.

https://doi.org/10.1182/blood-2018-151

Published: 2018

Journal Articles

Direct Oral Anticoagulants As Secondary Prophylaxis in Classical Myeloproliferative Neoplasms

Jacki Day, BS, Allison Deal, MS, Yue Wang, PhD, Benyam Muluneh, PharmD, Daniel Crona, PharmD, PhD, Brandi Reeves, MD

Blood (2018) 132 (Supplement 1): 5468.

https://doi.org/10.1182/blood-2018-99-116713

Published: 2018

Journal Articles

Upregulation of Tissue Factor May Contribute to Thrombosis in Polycythemia Vera and Essential Thrombocythemia

Brandi Reeves, MD, Soo Jin Kim, MS, Jihyun Song, PhD, Radhika Gangaraju, MD, Rafal Pawlinski, PhD, Perumal Thiagarajan, MD, Victor R. Gordeuk, MD, Nigel S. Key, MBChB, FRCP, Josef T. Prchal, MD

Blood (2018) 132 (Supplement 1): 2513.

https://doi.org/10.1182/blood-2018-99-117812

Published: 2018

Journal Articles

First Report on Overall Survival (OS) and Improved Progression Free Survival (PFS) in a Completed Phase 2a Study of Melflufen in Advanced Relapsed Refractory Multiple Myeloma (RRMM)

Paul G Richardson, MD, Sara Bringhen, MD, Peter M. Voorhees, MD, Torben Plesner, MD, Claudia Paba-Prada, MD, Ulf-Henrik Mellqvist, MD, Jeffrey A Zonder, MD, Brandi Reeves, MD, Antonio Palumbo, MD, Catriona Byrne, RN, Johan Harmenberg, MD PhD, Eva Nordstrom, MSc, MBA, Hanan Zubair, MSc, Jakob Lindberg, MD PhD, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 3150.

https://doi.org/10.1182/blood.V130.Suppl_1.3150.3150

Published: 2017

NARROW

An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Ropegiterferon Alfa-2b-Njft for Treatment Myeloproliferative Neoplasms: A Single Institution Experience

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

P-Selectin Deficiency Reduces Acute Vascular Complications but Not Chronic Organ Damage in Sickle Cell Mice

Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1

Direct Oral Anticoagulants As Secondary Prophylaxis in Classical Myeloproliferative Neoplasms

Upregulation of Tissue Factor May Contribute to Thrombosis in Polycythemia Vera and Essential Thrombocythemia

First Report on Overall Survival (OS) and Improved Progression Free Survival (PFS) in a Completed Phase 2a Study of Melflufen in Advanced Relapsed Refractory Multiple Myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only